BioCentury | Jan 22, 2021
Management Tracks

Woodman to guide Eisai’s cancer unit; plus Mengyu Lu joins Kirkland & Ellis in Hong Kong, and Splice Bio, Tarsus, Verastem, Fulcrum and more

Richard Woodman joined Eisai Inc., the U.S. pharma unit of Eisai Co. Ltd. (Tokyo:4523), as chief clinical officer of its oncology business group. Before joining Eisai, Woodman was CMO and head of R&D of Onconova Therapeutics...
BioCentury | Jan 22, 2021
Regulation

Jan. 21 Quick Takes: FDA approves ViiV’s long-acting HIV therapy; plus Menarini, Incyte, Moderna, Genentech

FDA approved ViiV Healthcare Ltd.’s Cabenuva, the first extended-release injectable regimen to treat HIV-1 infection in adults. The drug comes as a co-pack with two injectable drugs — ViiV’s cabotegravir...
BioCentury | Jan 21, 2021
Product Development

CAR NKT cells get early proof of concept with Kuur readout

Kuur’s early clinical NKT cell efficacy data add to a growing body of evidence that cell types beyond effector T cells hold promise as cancer therapies. Kuur Therapeutics, which re-launched and rebranded from Cell Medica...
BioCentury | Jan 21, 2021
Product Development

Jan. 20 Quick Takes: AZ, Daiichi get Enhertu approvals in gastric, breast cancer; plus EdiGene, Merck, Oxford, BMS and Omeros

Partners AstraZeneca plc (LSE:AZN; NASDAQ:AZN) and Daiichi Sankyo Co. Ltd. (Tokyo:4568) said HER2-targeted antibody-drug conjugate (ADC) Enhertu fam-trastuzumab deruxtecan-nxki received two additional approvals this week. On Tuesday, FDA approved an sBLA for Enhertu to treat locally...
BioCentury | Jan 21, 2021
Deals

Jan. 20 Quick Takes: Beam adds $260M; plus Lilly-Merus, Thermo Fisher-Mesa, Verve, Aclaris, ViGeneron-Daiichi Sankyo

Crossover investors supplied Beam Therapeutics Inc. (NASDAQ:BEAM) with $260 million in a private placement early Tuesday, purchasing 2.8 million shares at $93. The price is an 18% discount to Beam’s closing price Friday of $113.04....
BioCentury | Jan 21, 2021
Product Development

How spike mutations in SARS-CoV-2 variants affect vaccines, therapies: Data Byte

Recent papers suggest that although emerging SARS-CoV-2 variants have only minimally affected vaccine potency so far, vaccine and mAb developers need to take steps now to monitor for and counter escape...
BioCentury | Jan 21, 2021
Product Development

Merck KGaA’s bintrafusp alfa miss suggests there’s still more to learn about TGFβ

The Phase III miss for Merck KGaA’s bintrafusp alfa in non-small cell lung cancer takes one of the most promising indications for the GSK-partnered program out of contention, and raises questions about...
BioCentury | Jan 20, 2021
Finance

Rexgenero rebrands as Ikaxa, raises £40M following gene therapy deal

With an aim to bring its recently acquired synthetic gene delivery platform into the clinic, Rexgenero Ltd. has recapitalized and rebranded as cell and gene therapy company Ikaxa Ltd. The London-based biotech said undisclosed existing...
BioCentury | Jan 20, 2021
Emerging Company Profile

Aulos: Tackling the IL-2 space with computational biology

Apple Tree Partners launched Aulos into the crowded IL-2 space last week with a $40 million series A round and a computationally designed IL-2-binding antibody it thinks could have an edge in efficacy...
BioCentury | Jan 20, 2021
Finance

IPO queue bulges further as Adagene, NexImmune are among latest to file

After a record year for NASDAQ listings, a burgeoning queue of biopharmas seeking IPOs in 2021 swelled further late Tuesday as immuno-oncology companies Adagene and NexImmune filed for offerings. The pair joined seven therapeutics developers...
Items per page:
1 - 10 of 12682